Poniard Pharmaceuticals, Inc. (PARD)

OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
Apr 28, 2026, 4:00 PM EST
900.00%
Market Cap 15.00
Revenue (ttm) n/a
Net Income (ttm) -16.23M
Shares Out 1.50M
EPS (ttm) -3.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 3,103
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta -64.57
RSI 40.38
Earnings Date n/a

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1984
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol PARD
Full Company Profile

Financial Performance

News

There is no news available yet.